Britain is on the brink of a severe medicine supply crisis, according to urgent warnings from leading pharmacy figures. The situation, already grave due to shortages of common drugs like antibiotics and aspirin, has been significantly exacerbated by the war with Iran, which is now threatening medical supplies such as syringes and a wide array of other essential items, as stated by Sir Jim Mackey, head of the NHS.

Experts fear the UK faces a 'perfect storm' that will lead to record shortages of prescription drugs, potentially affecting even vital cancer medicines. Essential medications already in short supply include aspirin, crucial for millions to reduce heart attack and stroke risks; the blood pressure tablet ramipril; antidepressants sertraline and mirtazapine; folic acid for women hoping to conceive; and the antibiotic amoxicillin. Dr. James Davies, director of research and insights for Community Pharmacy England (CPE), described this development as 'very worrying,' noting that pharmacies are reporting unprecedented problems obtaining medicines at appropriate prices since data collection began in 2019.

Leyla Hannbeck, chief executive of the Independent Pharmacies Association, confirmed that suppliers and manufacturers anticipate the situation will worsen. She highlighted that these challenges existed even before the Middle East conflict, but the ongoing war is making it even more precarious. Patients dependent on their medications, including those needing cancer treatments, blood pressure drugs, and epilepsy medication like carbamazepine, face potential treatment delays or disruptions. Julia Halpin, who runs Being Well pharmacy, also noted the complete unavailability of Estradot, a popular HRT patch, from her wholesalers.

The scale of the problem is evident in the rise of UK Medicine Supply Issue Notifications. In 2021, there were 989 such notifications; however, February alone recorded 283, marking the highest ever in a single month. Another indicator is the significant increase in price concessions, where pharmacists seek Department of Health and Social Care (DHSC) approval to cover increased drug costs. Price concessions surged from 641 in 2020 to 1,496 in 2022, with 174 already recorded by February this year, suggesting a record number is likely for the year.

Multiple factors contribute to these shortages. Sourcing raw materials and packaging has become a mounting problem since the pandemic severely impacted supply chains. This has been compounded by manufacturers shutting down, severely delayed shipping, and the war in the Middle East driving up costs and further constraining raw ingredients. A major underlying issue is Britain's reliance on imported generic medicines, which constitute around 80 percent of all NHS prescribed drugs. The UK produces only about a quarter of these, primarily importing the rest from India and China, making it vulnerable to fluctuating global supply chains. Leyla Hannbeck added that the UK’s medicines budget is 'one of the lowest of any developed country,' rendering the market unattractive to manufacturers.

When supply is significantly disrupted, the Department of Health can issue a Serious Shortage Protocol (SSP), allowing pharmacists to supply an alternative medicine. An SSP, for instance, was issued for Fixapost eye drops, allowing Vizilatan Duo as an alternative. However, introducing swaps can cause problems for patients, especially with significant dose differences, altered effectiveness, and the absence of standard alternatives for medicines used to treat various conditions, such as amitriptyline for depression and chronic pain. Malcolm Harrison of the Company Chemists Association cited the example of Creon, where one manufacturer's withdrawal led to shortages.

A DHSC spokesperson stated that the 'vast majority of the UK’s licensed medicines are in good supply,' emphasizing efforts to strengthen supply resilience through financial incentives for manufacturing and engagement with partner countries. They assured that processes are in place to mitigate risks, including using alternative medicines. Pharmacy bodies advise patients to shop around if their designated pharmacy cannot provide a required prescription.

The top ten drugs experiencing shortages, with figures from Open Prescribing (November 2025 data), include:

1. Lansoprazole: 3.01 million prescription items. Shortage affects 30mg orodispersible tablets, 28 pack, used for heartburn, reflux, and stomach ulcers.

2. Ramipril: 2.8 million prescription items. Shortage affects 10mg, 5mg, 1.25mg, 2.5mg capsules and tablets, used for high blood pressure, heart failure, and stroke/heart attack prevention.

3. Sertraline: 2.05 million prescription items. Shortage affects 50mg tablets, 28 pack, an antidepressant for depression, OCD, panic disorder, PTSD, and social anxiety disorder.

4. Aspirin: 1.6 million prescription items. Shortage affects 75mg dispersible and gastro-resistant tablets, 28 and 100 packs, used to reduce heart attack and stroke risk.

5. Co-codamol: 1.175 million prescription items. Shortage affects 30mg/500mg (30, 100 tablets) and 8mg/500mg capsules/effervescent tablets (32, 100 packs), a pain relief combination.

6. Mirtazapine: 1.09 million prescription items. Shortage affects 15mg tablets, 28 pack, an antidepressant for depression, sometimes OCD and anxiety.

7. Folic Acid: 758,000 prescription items. Shortage affects 400 microgram tablets, 90 pack; 45mg tablets, 28 pack, used to prevent birth defects and treat anaemia.

8. Fluoxetine: 658,000 prescription items. Shortage affects 20mg capsules, 30 tablets, for depression, OCD, and bulimia.

9. Propranolol: 652,000 prescription items. Shortage affects 80mg and 160mg modified-release capsules, 28 pack, a beta-blocker for heart problems, anxiety, and migraine.

10. Amoxicillin: 625,000 prescription items. Shortage affects 250mg/5ml oral suspension, 100 pack, an antibiotic for various bacterial infections.